Evidence map›Paper›PMID 36794815›Full record

ArticleGut microbes

Using fecal immmunochemical cartridges for gut microbiome analysis within a colorectal cancer screening program.

Stefanie Brezina, Martin Borkovec, Andreas Baierl, Fabienne Bastian, Andreas Futschik, Nikolaus Gasche, Thomas Gruenberger, Michael Hallas, Christian Jannsen, Gernot Leeb and 3 more

Open access · goldAbstract read
In one paragraph

Article in Gut microbes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. The therapeutic promise of probioticFrontiers in microbiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Stefanie BrezinaCenter for Cancer Research, Medical University of Vienna, Vienna, Austria.ORCID 0000-0001-5238-6900
Martin BorkovecCenter for Cancer Research, Medical University of Vienna, Vienna, Austria.
Andreas BaierlDepartment of Statistics and Operations Research, University of Vienna, Vienna, Austria.ORCID 0000-0002-5329-9507
Fabienne BastianDepartment of Surgery, Clinic Favoriten, Vienna, Austria.
Andreas FutschikDepartment of Applied Statistics, Johannes Kepler University Linz, Linz, Austria.
Nikolaus GascheBiome Diagnostics GmbH, Langenzersdorf, Austria.
Thomas GruenbergerDepartment of Surgery, Clinic Favoriten, Vienna, Austria.
Michael HallasInstitute of Pathology and Bacteriology, Clinic Favoriten, Vienna, Austria.
Christian JannsenBiome Diagnostics GmbH, Langenzersdorf, Austria.
Gernot LeebDepartment of Internal Medicine, Hospital Oberpullendorf, Oberpullendorf, Austria.ORCID 0000-0003-3889-5594
Rebecca LutzDepartment of Surgery, Clinic Favoriten, Vienna, Austria.
Barbara SladekBiome Diagnostics GmbH, Langenzersdorf, Austria.
Andrea GsurCenter for Cancer Research, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-9795-1528
Comprehensive Cancer Center Vienna · ATJohannes Kepler University of Linz · ATKrankenhaus Oberndorf · ATUniversity of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The colorectal cancer (CRC) screening program B-PREDICT is an invited two-stage screening project using a fecal immunochemical test (FIT) for initial screening followed by a colonoscopy for those with a positive FIT. Since the gut microbiome likely plays a role in the etiology of CRC, microbiome-based biomarkers in combination with FIT could be a promising tool for optimizing CRC screening. Therefore, we evaluated the usability of FIT cartridges for microbiome analysis and compared it to Stool Collection and Preservation Tubes. Corresponding FIT cartridges as well as Stool Collection and Preservation Tubes were collected from participants of the B-PREDICT screening program to perform 16S rRNA gene sequencing. We calculated intraclass correlation coefficients (ICCs) based on center log ratio transformed abundances and used ALDEx2 to test for significantly differential abundant taxa between the two sample types. Additionally, FIT and Stool Collection and Preservation Tube triplicate samples were obtained from volunteers to estimate variance components of microbial abundances. FIT and Preservation Tube samples produce highly similar microbiome profiles which cluster according to subject. Significant differences between the two sample types can be found for abundances of some bacterial taxa (e.g. 33 genera) but are minor compared to the differences between the subjects. Analysis of triplicate samples revealed slightly worse repeatability of results for FIT than for Preservation Tube samples. Our findings indicate that FIT cartridges are appropriate for gut microbiome analysis nested within CRC screening programs.

Indexed as

Colorectal NeoplasmsGastrointestinal MicrobiomeMicrobiotaEarly Detection of CancerFecesHumansRNA, Ribosomal, 16SRNA, Ribosomal, 16S16S rRNA sequencingcolorectal cancerFITMicrobiomeNORGEN

Identifiers

PMID36794815
PMCPMC9980522
OpenAlexW4321004306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.